Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method

Clinical Chemistry

Volumn 50, Issue 4, 2004, Pages 741-746

  Kang, Hyunseok Peter ^a   Scott, Mitchell G ^a   Joe, Bonnie N ^b   Narra, Vamsi ^b   Heiken, Jay ^b   Parvin, Curtis A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENAZO DYE; AZO DYE; CALCIUM; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOVERSETAMIDE; ORTHO CRESOL; ORTHO CRESOLPHTHALEIN; UNCLASSIFIED DRUG;

ANALYTICAL ERROR; ARTICLE; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; HUMAN; IN VITRO STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA; PREDICTION;

CALCIUM; CONTRAST MEDIA; FALSE POSITIVE REACTIONS; GADOLINIUM; GADOLINIUM DTPA; HUMANS; INDICATORS AND REAGENTS; MODELS, BIOLOGICAL; ORGANOMETALLIC COMPOUNDS; PHENOLPHTHALEINS; REFERENCE VALUES; TIME FACTORS;

EID: 1842451550     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.028886     Document Type: Article

References (13)

1. Bourne GW, Trifaro JM. The gadolinium ion: a potent blocker of calcium channels and catecholamine release from cultured chromaffin cells. Neuroscience 1982;7:1615-22.
2. Krasnow N. Effects of lanthanum and gadolinium ions on cardiac sarcoplasmic reticulum. Biochim Biophys Acta 1972;282:187-94.
3. Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging 2001;12:309-14.
4. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991;180:85-9.
5. Prince MR, Arnoldus C, Frisoli JK. Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 1996;6:162-6.
6. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. J Magn Reson Imaging 1999;10:477-84.
7. Murphy KJ, Brunberg JA, Cohan RH. Adverse reactions to gadolinium contrast media: a review of 36 cases. AJR Am J Roentgenol 1996;167:847-9.
8. Lin J, Idee JM, Port M, Diai A, Berthommier C, Robert M, et al. Interference of magnetic resonance imaging contrast agents with the serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 1999;21:931-43.
9. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination of serum calcium. Scand J Clin Lab Invest 1995;55:421-6.
10. Prince MR, Erel HE, Lent RW, Blumenfeld J, Kent KC, Bush HL, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003;227:639-46.
11. Doorenbos CJ, Ozyilmaz A, van Wijnen M. Severe pseudohypocalcemia after gadolinium-enhanced magnetic resonance angiography. N Engl J Med 2003;349:817-8.
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
13. Sauerbrei W, Royston P. Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials. J R Stat Soc A 1999;162:71-94.